Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Primary Cilia as Metabolic Regulators in Cholangiocyte Health and Disease

Award Number: R01CA314164
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/03/2026
PERIOD OF PERFORMANCE END DATE: 06/30/2031

Group Awards By:

View Award Description

Primary Cilia as Metabolic Regulators in Cholangiocyte Health and Disease - Primary cilia are multisensory organelles that function as cellular antennae. Ciliary defects in cholangiocytes and/or the loss of primary cilia have been linked to biliary tract diseases like polycystic liver disease (PLD) and cholangiocarcinoma (CCA). A deeper understanding of cilia-regulated signaling pathways and the mechanisms underlying ciliary loss in diseased cholangiocytes is essential for developing novel ciliotherapy-based treatments aimed at restoring ciliary function. The long-term goals of this research are to understand the pathogenesis of the cholangiociliopathies and to develop innovative therapeutic strategies for their treatment. The overall objective for this proposal is to explore the novel hypothesis that the cholangiocyte primary cilium regulates the cellular metabolic phenotype. The CENTRAL HYPOTHESES are that: (a) sensory functions of primary cilia negatively regulate glucose consumption, and (b) in CCA, defects on primary cilia induce a metabolic switch to aerobic glycolysis. Two integrated but independent aims will test these hypotheses. Aim 1, This aim will determine how primary cilia loss drives metabolic reprogramming in cholangiocytes and contributes to cholangiocarcinoma progression. In this aim, we will investigate the consequences of ciliary dysfunction on cellular metabolism (glycolytic switch) and tumor behavior, using normal (ciliated vs. deciliated) and CCA cell lines, xenograft/orthotopic models, and human CCA specimens. We will also evaluate whether reversing the Warburg effect (via HK2 inhibition) slows CCA cell proliferation and tumor growth. We will characterize metabolic profiles of ciliary defective cells compared to normal ciliated cells by Seahorse Real-Time Cell Metabolic analyzer, molecular cell biology, immunohistochemistry, RNAseq, and metabolomics approaches. Aim 2, This aim will elucidate the cilia-dependent signaling mechanism (P2Y¨PKA¨LKB1¨HIF1ƒ¿ pathway) that regulates cholangiocyte metabolism, and test therapeutic strategies to restore this pathway in cholangiocarcinoma. This aim addresses the mechanism: we will dissect how ciliary sensory functions normally suppress HIF1ƒ¿ and glycolysis via LKB1/AMPK. We will use targeted interventions (e.g., activate LKB1 with a small molecule or inhibit HIF1ƒ¿) in cilia-defective CCA models to see if we can normalize metabolism and impede tumor growth. The aim will also incorporate verifying this pathway in patient samples (e.g., correlation of cilia status with LKB1 activation and HIF1ƒ¿ targets in CCA tissues). Impact: These experiments, conducted by an experienced and multidisciplinary team, will uncover novel and generalizable information on the fundamental mechanisms of ciliary-dependent regulation of the metabolic switch that influence the survival of cholangiocytes. Successful completion of these aims will uncover a novel metabolic vulnerability in CCA (the ciliary-Warburg axis) and provide preclinical evidence for ciliotherapy-based metabolic interventions as a new treatment strategy for cholangiocarcinoma. Animal studies are required to determine how primary cilia regulate cholangiocarcinoma metabolism and growth in vivo and to evaluate the therapeutic efficacy of targeting the ciliary-Warburg axis in physiologically relevant disease models.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $626,943 )
2026	2026	REGENTS OF THE UNIVERSITY OF MINNESOTA	2221 UNIVERSITY AVE SE STE 100	MINNEAPOLIS	MN	55414	HENNEPIN	USA	Cancer Biology Research	000	1	7/3/2026	NEW	$626,943
														Subtotal = $626,943

Grand Total All Awards = $626,943

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Primary Cilia as Metabolic Regulators in Cholangiocyte Health and Disease

Award Number: R01CA314164

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/03/2026

PERIOD OF PERFORMANCE END DATE: 06/30/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer